Literature DB >> 9630404

The effects of macrolides on the expression of bacterial virulence mechanisms.

T R Shryock1, J E Mortensen, M Baumholtz.   

Abstract

Macrolides are unique among the various classes of antimicrobial agents because of the manner in which they interact with pathogens and the host immune system to produce a clinical response. Conventional efficacy explanations require the serum or tissue concentration of the macrolide to exceed the MIC of the macrolide to account for bacteriostatic activity. However, at concentrations below the MIC, there are other effects on the expression of proteinaceous virulence factors which could prevent the pathogen from establishing or expanding an infection. The purpose of this review is to describe these effects and to provide an in-vivo scenario delineating the role of macrolides and leucocytes as they contribute to clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630404     DOI: 10.1093/jac/41.5.505

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

3.  Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach.

Authors:  Amir Atabak Ronaghinia; Julie Melsted Birch; Henrik Lauritz Frandsen; Pierre-Louis Toutain; Peter Damborg; Tina Struve
Journal:  Vet Res       Date:  2021-02-27       Impact factor: 3.683

4.  Whole-Genome Analysis of Antimicrobial-Resistant and Extraintestinal Pathogenic Escherichia coli in River Water.

Authors:  Ryota Gomi; Tomonari Matsuda; Yasufumi Matsumura; Masaki Yamamoto; Michio Tanaka; Satoshi Ichiyama; Minoru Yoneda
Journal:  Appl Environ Microbiol       Date:  2017-02-15       Impact factor: 4.792

5.  Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.

Authors:  J Plouffe; D B Schwartz; A Kolokathis; B W Sherman; P M Arnow; J A Gezon; B Suh; A Anzuetto; R N Greenberg; M Niederman; J A Paladino; J A Ramirez; J Inverso; C A Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  Effects of the macrolide drug tylosin on chronic diarrhea in rhesus macaques (Macaca mulatta).

Authors:  Rebecca S Blackwood; Ross P Tarara; Kari L Christe; Abigail Spinner; Nicholas W Lerche
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

Review 7.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

8.  The effect of the macrolide antibiotic tylosin on microbial diversity in the canine small intestine as demonstrated by massive parallel 16S rRNA gene sequencing.

Authors:  Jan S Suchodolski; Scot E Dowd; Elias Westermarck; Jörg M Steiner; Randy D Wolcott; Thomas Spillmann; Jaana A Harmoinen
Journal:  BMC Microbiol       Date:  2009-10-02       Impact factor: 3.605

9.  Combination therapy for airflow limitation in COPD.

Authors:  Mostafa Ghanei; Leila Hoseini Nezhad; Ali Amini Harandi; Farshid Alaeddini; Majid Shohrati; Jafar Aslani
Journal:  Daru       Date:  2012-08-28       Impact factor: 3.117

10.  Assessing antibiotic sorption in soil: a literature review and new case studies on sulfonamides and macrolides.

Authors:  Stacia R Wegst-Uhrich; Divina Ag Navarro; Lisa Zimmerman; Diana S Aga
Journal:  Chem Cent J       Date:  2014-01-17       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.